Detection and nonoperative management of pediatric developmental dysplasia of the hip in infants ...

389 Pages·2014·4.13 MB·English

DETECTION AND NONOPERATIVE
MANAGEMENT OF PEDIATRIC
DEVELOPMENTAL DYSPLASIA OF THE HIP IN
INFANTS UP TO SIX MONTHS OF AGE

EVIDENCE-BASED CLINICAL PRACTICE
GUIDELINE

Adopted by the American Academy of Orthopaedic Surgeons
Board of Directors
September 5, 2014

This guideline has been endorsed by the following organizations:

i
Disclaimer
This Clinical Practice Guideline was developed by an AAOS clinician volunteer Work
Group based on a systematic review of the current scientific and clinical information and
accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not
intended to be a fixed protocol, as some patients may require more or less treatment or
different means of diagnosis. Clinical patients may not necessarily be the same as those
found in a clinical trial. Patient care and treatment should always be based on a
clinician’s independent medical judgment, given the individual patient’s clinical
circumstances.
Disclosure Requirement
In accordance with AAOS policy, all individuals whose names appear as authors or
contributors to Clinical Practice Guideline filed a disclosure statement as part of the
submission process. All panel members provided full disclosure of potential conflicts of
interest prior to voting on the recommendations contained within this Clinical Practice
Guidelines.
Funding Source
This Clinical Practice Guideline was funded exclusively by the American Academy of
Orthopaedic Surgeons who received no funding from outside commercial sources to
support the development of this document.
FDA Clearance
Some drugs or medical devices referenced or described in this Clinical Practice Guideline
may not have been cleared by the Food and Drug Administration (FDA) or may have
been cleared for a specific use only. The FDA has stated that it is the responsibility of the
physician to determine the FDA clearance status of each drug or device he or she wishes
to use in clinical practice.
Copyright
All rights reserved. No part of this Clinical Practice Guideline may be reproduced, stored
in a retrieval system, or transmitted, in any form, or by any means, electronic,
mechanical, photocopying, recording, or otherwise, without prior written permission
from the AAOS.
Published 2014 by the American Academy of Orthopaedic Surgeons
6300 North River Road
Rosemont, IL 60018
First Edition
Copyright 2014 by the American Academy of Orthopaedic Surgeons

ii
I. SUMMARY OF RECOMMENDATIONS
The following is a summary of the recommendations of the AAOS’ clinical practice
guideline on Detection and Nonoperative Management of Pediatric Developmental
Dysplasia of the Hip in Infants up to Six Months of Age. All readers of this summary are
strongly urged to consult the full guideline and evidence report for this information. We
are confident that those who read the full guideline and evidence report will see that the
recommendations were developed using systematic evidence-based processes designed to
combat bias, enhance transparency, and promote reproducibility.
This summary of recommendations is not intended to stand alone. Treatment decisions
should be made in light of all circumstances presented by the patient. Treatments and
procedures applicable to the individual patient rely on mutual communication between
patient guardian, physician, and other healthcare practitioners.
Overall
Strength of
Strength Evidence Description of Evidence Strength Strength Visual
Evidence from two or more “High” strength
Strong Strong studies with consistent findings for
recommending for or against the intervention.
Evidence from two or more “Moderate”
strength studies with consistent findings, or
Moderate Moderate
evidence from a single “High” quality study for

recommending for or against the intervention.
Evidence from one or more “Low” strength
studies with consistent findings or evidence
Low Strength from a single “Moderate” strength study for
Evidence or recommending for against the intervention or
Limited
Conflicting diagnostic or the evidence is insufficient or

Evidence conflicting and does not allow a
recommendation for or against the
intervention.
There is no supporting evidence. In the absence
of reliable evidence, the work group is making
a recommendation based on their clinical
Consensus* No Evidence opinion. Consensus recommendations can only
be created when not establishing a
recommendation could have catastrophic
consequences.

iii
UNIVERSAL ULTRASOUND SCREENING
Moderate evidence supports not performing universal ultrasound screening
of newborn infants.
Strength of Recommendation: Moderate
Description: Evidence from two or more “Moderate” strength studies with consistent
findings, or evidence from a single “High” quality study for recommending for or against
the intervention. A Moderate recommendation means that the benefits exceed the
potential harm (or that the potential harm clearly exceeds the benefits in the case of a
negative recommendation), but the quality/applicability of the supporting evidence is not
as strong.
EVALUATION OF INFANTS WITH RISK FACTORS FOR DDH
Moderate evidence supports performing an imaging study before 6 months
of age in infants with one or more of the following risk factors: breech
presentation, family history, or history of clinical instability.
Strength of Recommendation: Moderate
Description: Evidence from two or more “Moderate” strength studies with consistent
findings, or evidence from a single “High” quality study for recommending for or against
the intervention. A Moderate recommendation means that the benefits exceed the
potential harm (or that the potential harm clearly exceeds the benefits in the case of a
negative recommendation), but the quality/applicability of the supporting evidence is not
as strong.
IMAGING OF THE UNSTABLE HIP
Limited evidence supports that the practitioner might obtain an ultrasound in
infants less than 6 weeks of age with a positive instability examination to
guide the decision to initiate brace treatment.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
iv
IMAGING OF THE INFANT HIP
Limited evidence supports the use of an AP pelvis radiograph instead of an
ultrasound to assess DDH in infants beginning at 4 months of age.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
SURVEILLANCE AFTER NORMAL INFANT HIP EXAM
Limited evidence supports that a practitioner re-examine infants previously
screened as having a normal hip examination on subsequent visits prior to 6
months of age.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
STABLE HIP WITH ULTRASOUND IMAGING ABNORMALITIES
Limited evidence supports observation without a brace for infants with a
clinically stable hip with morphologic ultrasound imaging abnormalities.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.

v
TREATMENT OF CLINICAL INSTABILITY
Limited evidence supports either immediate or delayed (2-9 weeks) brace
treatment for hips with a positive instability exam.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
TYPE OF BRACE FOR THE UNSTABLE HIP
Limited evidence supports use of the von Rosen splint over Pavlik, Craig, or
Frejka splints for initial treatment of an unstable hip
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
MONITORING OF PATIENTS DURING BRACE TREATMENT
Limited evidence supports that the practitioner perform serial physical
examinations and periodic imaging assessments (ultrasound or radiograph
based on age) during management for unstable infant hips.
Strength of Recommendation: Limited
Description: Evidence from one or more “Low” strength studies with consistent findings,
or evidence from a single Moderate quality study recommending for or against the
intervention or diagnostic. A Limited recommendation means that the quality of the
supporting evidence is unconvincing, or that well-conducted studies show little clear
advantage to one approach over another.
vi
TABLE OF CONTENTS
I. Summary of Recommendations ................................................................................. iii
Universal Ultrasound Screening .................................................................................... iv
Evaluation of Infants with Risk Factors for DDH ......................................................... iv
Imaging of the Unstable Hip .......................................................................................... iv
Imaging of the Infant Hip ............................................................................................... v
Surveillance After Normal Infant Hip Exam .................................................................. v
Stable Hip with Ultrasound Imaging Abnormalities ...................................................... v
Treatment of Clinical Instability .................................................................................... vi
Type of Brace for the Unstable Hip ............................................................................... vi
Monitoring of Patients During Brace Treatment ........................................................... vi
Table of Contents .............................................................................................................. vii
List of Tables ...................................................................................................................... 1
List of Figures ..................................................................................................................... 4
II. Introduction ................................................................................................................. 5
Overview ..................................................................................................................... 5
Goals and Rationale .................................................................................................... 5
Intended Users ............................................................................................................ 5
Patient Population ....................................................................................................... 6
Burden Of Disease/Incidence And Prevalence ........................................................... 6
Natural History............................................................................................................ 7
Etiology ....................................................................................................................... 8
Risk factors ................................................................................................................. 8
Emotional And Physical Impact ................................................................................. 8
Potential Benefits, Harms, And Contraindications ..................................................... 8
III. Methods................................................................................................................... 9
Formulating Preliminary Recommendations ................................................................ 10
Full Disclosure Information .......................................................................................... 10
Study Selection Criteria ................................................................................................ 10
Best Evidence Synthesis ............................................................................................... 11
Minimally Clinically Important Improvement.............................................................. 11
Literature Searches........................................................................................................ 12
Methods for Evaluating Evidence ................................................................................. 12
Studies of Intervention/Prevention ........................................................................... 12
Studies of Screening and Diagnostic Tests ............................................................... 15
Studies of Prognostics ............................................................................................... 17
Final Strength of Evidence........................................................................................ 18
Defining the Strength of the Recommendations ........................................................... 18
Wording of the Final Recommendations ...................................................................... 19
Applying the Recommendations to Clinical Practice ................................................... 20
Voting on the Recommendations .................................................................................. 20
Statistical Methods ........................................................................................................ 20
Peer Review .................................................................................................................. 22
Public Commentary ...................................................................................................... 23
The AAOS Guideline Approval Process ...................................................................... 23
Revision Plans ............................................................................................................... 23
vii
Guideline Dissemination Plans ..................................................................................... 23
IV. Recommendations ................................................................................................. 21
Number and Strength of Articles per Recommendation ............................................... 21
Universal Ultrasound Screening ................................................................................... 22
Rationale ................................................................................................................... 22
Supporting Evidence ................................................................................................. 23
Evaluation of Infants with Risk Factors for DDH ........................................................ 29
Rationale ................................................................................................................... 29
Supporting Evidence ................................................................................................. 23
Imaging of the Unstable Hip ......................................................................................... 52
Rationale ................................................................................................................... 52
Supporting Evidence ................................................................................................. 53
Imaging of the Infant Hip ............................................................................................. 64
Rationale ................................................................................................................... 64
Supporting Evidence ................................................................................................. 65
Surveillance After Normal Infant Hip Exam ................................................................ 67
Rationale ................................................................................................................... 67
Supporting Evidence ................................................................................................. 68
Stable Hip with Ultrasound Imaging Abnormalities .................................................... 70
Rationale ................................................................................................................... 70
Supporting Evidence ................................................................................................. 71
Treatment of Clinical Instability ................................................................................... 73
Rationale ................................................................................................................... 73
Supporting Evidence ................................................................................................. 74
Type of Brace for the Unstable Hip .............................................................................. 85
Rationale ................................................................................................................... 85
Supporting Evidence ................................................................................................. 86
Monitoring of Patients During Brace Treatment .......................................................... 99
Rationale ................................................................................................................... 99
Supporting Evidence ............................................................................................... 100
V. Future Research ...................................................................................................... 104
VI. Appendixes ......................................................................................................... 106
Appendix I. Work Group Roster ................................................................................. 106
Guidelines Oversight ChairS .................................................................................. 108
AAOS Clinical Practice Guidelines Section Leader ............................................... 108
AAOS Council on Research and Quality Chair ...................................................... 108
Additional Contributing Members .......................................................................... 108
AAOS Staff ............................................................................................................. 109
Former Staff ............................................................................................................ 109
Appendix II ................................................................................................................. 110
AAOS Bodies That Approved This Clinical Practice Guideline ............................ 110
Appendix III ................................................................................................................ 111
Study Attrition Flowchart ....................................................................................... 111
Appendix IV................................................................................................................ 112
Literature Search Strategies .................................................................................... 112
Appendix V ................................................................................................................. 116
viii
Evaluation of Quality .............................................................................................. 116
Applicability ........................................................................................................... 121
Appendix VI................................................................................................................ 124
Opinion Based Recommendations .......................................................................... 124
Appendix VII .............................................................................................................. 126
Structured Peer Review Form ................................................................................. 126
Appendix VIII ............................................................................................................. 128
Participating Peer Review Organizations ............................................................... 128
Appendix IX................................................................................................................ 129
Conflict of Interest .................................................................................................. 129
Appendix X ................................................................................................................. 131
Bibliographies ......................................................................................................... 131
Introduction References .......................................................................................... 131
Methods references ................................................................................................. 134
Included Studies ...................................................................................................... 135
Excluded Studies ..................................................................................................... 139
Additional Articles Recalled from Systematic Review Screening ......................... 351
Appendix XI................................................................................................................ 357
Natural History Figures........................................................................................... 357
Appendix XII .............................................................................................................. 366
Letters of Endorsement from External Organizations ............................................ 366

ix
List of Tables
Table 1. Relationship between Quality and Domain Scores for Interventions ................. 13
Table 2. Brief Description of the PRECIS Questions and Domains................................. 14
Table 3. Relationship between Applicability and Domain Scores for Studies of
Treatments......................................................................................................................... 15
Table 4. Relationship Between Domain Scores and Quality of Screening/Diagnostic Tests
........................................................................................................................................... 16
Table 5. Relationship Between Domain Scores and Applicability for Studies of
Screening/Diagnostic Tests ............................................................................................... 17
Table 6. Relationship Between Quality and Domain Scores for Studies of Prognostics . 17
Table 7. Relationship Between Domain Scores and Applicability for Studies of
Prognostics ........................................................................................................................ 18
Table 8. Strength of Recommendation Descriptions ........................................................ 19
Table 9. AAOS Guideline Language Stems ..................................................................... 19
Table 10. Clinical Applicability: Interpreting the Strength of a Recommendation .......... 20
Table 11. Interpreting Likelihood Ratios .......................................................................... 21
Table 12. Quality and Applicability: Studies for Universal Ultrasound Screening .......... 23
Table 13. Imaging of the Unstable Hip (Universal Ultrasound Versus Risk-Stratified
Ultrasound) ....................................................................................................................... 25
Table 14. Quality and Applicability: Studies for Evaluation of Infants with Risk Factors
for DDH ............................................................................................................................ 23
Table 15. Quality and Applicability: Prognostic Studies for Evaluation of Infants with
Risk Factors for DDH ....................................................................................................... 24
Table 16. Quality and Applicability for Evaluation of Infants with Risk Factors for DDH
........................................................................................................................................... 28
Table 17. Quality and Applicability for Evaluation of Infants with Risk Factors for DDH
........................................................................................................................................... 30
Table 18. Evaluation of Infants with Risk Factors for DDH ............................................ 32
Table 19. Evaluation of Infants with Risk Factors for DDH (Accuracy of Physical Exam)
........................................................................................................................................... 33
Table 20. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Breech) ........ 34
Table 21. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Sex) ............. 35
Table 22. Evaluation of Infants with Risk Factors for DDH (Incidence Study: Sex) ...... 36
Table 23. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Click) ........... 36
Table 24. Evaluation of Infants with Risk Factors for DDH (Incidence Study: Click) .... 37
Table 25. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Gender and
Breech) .............................................................................................................................. 37
Table 26. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Gender and
Family History) ................................................................................................................. 38
Table 27. Evaluation of Infants with Risk Factors for DDH (Risk Factor: First Born) ... 38
Table 28. Evaluation of Infants with Risk Factors for DDH (Incidence Study: First Born)
........................................................................................................................................... 39
Table 29. Evaluation of Infants with Risk Factors for DDH (Risk Factor: Gender and
Swaddling) ........................................................................................................................ 39
1